Phase I trial of weekly gemcitabin and concurrent radiotherapy in patients with inoperable non small cell lung cancer.

Pierluigi Granone, Stefano Margaritora, Alfredo Cesario, Lucio Trodella, Salvatore Valente, Adriana Turriziani, Giuseppe Macis, Giuseppe Maria Corbo, Numa Cellini, R. M. D'Angelillo, G. Gualano, S. Ramella, D. Galetta

Risultato della ricerca: Contributo in rivistaArticolo in rivista


PURPOSE: To report the evidence of a phase I trial planned to determine the maximum-tolerated dose (MTD) and related toxicity of weekly gemcitabine (GEM) and concurrent radiotherapy in patients with non--small-cell lung cancer (NSCLC). In addition, the response to treatment was evaluated and reported. PATIENTS AND METHODS: Thirty-six patients with histologically confirmed NSCLC deemed unresectable because of advanced stage were observed and treated according to a combined chemoradiation protocol with GEM as chemotherapeutic agent. GEM was given weekly for 5 consecutive weeks as a 30-minute intravenous infusion concurrent with radiotherapy (1.8 Gy/d; total dose, 50.4 Gy). The initial dose was 100 mg/m(2). Pulmonary, esophageal, cardiac, hematologic, and skin toxicities were assessed. The dose of GEM was increased by 50 mg/m(2) up to a dose of 250 mg/m(2); an additional increase by 25 mg/m(2) up to the MTD was planned and realized. Three patients were enrolled for each dose level. RESULTS: Dose-limiting toxicity was identified for the 375-mg/m(2) level with two episodes of grade 2 esophagitis and two of grade 3 pulmonary actinic interstitial disease. The weekly dose of GEM 350 mg/m(2) was well tolerated. CONCLUSION: A weekly GEM dose of 350 mg/m(2) concurrent with radiotherapy was well tolerated. Promising results regarding response to treatment were observed and reported.
Lingua originaleEnglish
pagine (da-a)804-810
Numero di pagine7
RivistaJournal of Clinical Oncology
Stato di pubblicazionePubblicato - 2002


  • radiotherapy


Entra nei temi di ricerca di 'Phase I trial of weekly gemcitabin and concurrent radiotherapy in patients with inoperable non small cell lung cancer.'. Insieme formano una fingerprint unica.

Cita questo